Boston Immune Technologies & Therapeutics

Boston Immune Technologies & TherapeuticsAbout

Verify this business
4.0 9 Reviews
www.bostonimmunetech.com
Write a review
Reviews9PhotosWidgetsDetails

About company

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.